PBYI - Puma Biotechnology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.40
-0.25 (-0.59%)
As of 9:34AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close42.65
Open42.85
Bid41.75 x 1800
Ask46.75 x 900
Day's Range42.20 - 42.85
52 Week Range41.30 - 136.90
Volume10,179
Avg. Volume919,968
Market Cap1.612B
Beta1.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Puma Biotechnology: Recent Developments and Recommendations
    Market Realist7 days ago

    Puma Biotechnology: Recent Developments and Recommendations

    In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.

  • How Puma Biotechnology Performed in Q2 2018
    Market Realist7 days ago

    How Puma Biotechnology Performed in Q2 2018

    Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.

  • Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales
    Zacks7 days ago

    Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

    Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.

  • Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
    Zacks8 days ago

    Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates

    Puma Biotech (PBYI) delivered earnings and revenue surprises of 53.17% and 0.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press8 days ago

    Puma Biotech: 2Q Earnings Snapshot

    The Los Angeles-based company said it had a loss of $1.17 per share. Losses, adjusted for stock option expense, came to 59 cents per share. The biopharmaceutical company posted revenue of $50.8 million ...

  • MarketWatch8 days ago

    Puma Bio shares jump 19% on narrower quarterly loss, bigger sales

    Shares of Puma Biotechnology Inc. (pbyi) rose more than 19% in the extended session Thursday after the company reported a narrower-than-expected quarterly loss and sales came in above forecasts. Puma said it lost $44.3 million, or $1.17 a share, in the second quarter, compared with a net loss of $77.8 million, or $2.10 a share, in the year-ago period. Puma in July got approval from the U.S. Food and Drug Administration for Nerlynx, used in the treatment of breast cancer, and the company began shipment to wholesalers at the end of that month.

  • What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?
    Zacks10 days ago

    What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?

    On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.

  • Puma Biotechnology Enters into Collaboration with Strata Oncology
    Market Realistlast month

    Puma Biotechnology Enters into Collaboration with Strata Oncology

    Puma Biotechnology Enters into Collaboration with Strata OncologyPuma’s collaboration with Strata Oncology

  • Here's Why Puma Biotechnology Rose 11.7% in June
    Motley Foollast month

    Here's Why Puma Biotechnology Rose 11.7% in June

    The biotech had a reverse of fortune for its lead drug in Europe

  • How Puma Biotechnology Is Positioned Financially before Q2 2018
    Market Realistlast month

    How Puma Biotechnology Is Positioned Financially before Q2 2018

    Puma Biotechnology (PBYI) generated revenues of $66.5 million in the first quarter, including revenues of $36 million and $30.5 million from product sales and licenses, respectively.

  • How Analysts Are Rating Puma Biotechnology in July
    Market Realistlast month

    How Analysts Are Rating Puma Biotechnology in July

    The positive recommendation from CHMP comes after a reexamination of negative recommendations at the meeting for the MAA on February 23. On July 5, the company had a consensus 12-month target price of $94.17, which represents a 60.29% return on investment over the next 12 months. On July 5, Incyte had a consensus 12-month target price of $83.71, which represents an 18.65% return on investment over the next 12 months.

  • Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote
    Zacks2 months ago

    Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote

    Puma Biotechnology's (PBYI) marketing application seeking approval for neratinib in breast cancer gets positive CHMP trend vote, following a negative opinion in February.

  • Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod
    Zacks2 months ago

    Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod

    The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.

  • Why Puma Biotechnology Stock Soared Today
    Motley Fool2 months ago

    Why Puma Biotechnology Stock Soared Today

    Puma's breast cancer drug got a second look by European regulators today, sending the drugmaker's shares soaring.

  • Why General Electric, Puma Biotechnology, and Lennar Jumped Today
    Motley Fool2 months ago

    Why General Electric, Puma Biotechnology, and Lennar Jumped Today

    Find out which of these stocks is the biggest winner.

  • Reuters2 months ago

    Puma Biotech says Europe likely to approve breast cancer drug

    Puma shares were up 27.5 percent at $65.15 in premarket trading. The decision followed a reexamination of the negative opinion announced by the Committee for Medicinal Products for Human Use in February, the company said. The committee will hold a final vote at its next meeting, Puma said.

  • Former Puma Biotech executive gets U.S. prison term for insider trading
    Reuters2 months ago

    Former Puma Biotech executive gets U.S. prison term for insider trading

    A former Puma Biotechnology Inc (PBYI.O) executive was sentenced on Wednesday to 2-1/4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing. Robert Gadimian, 48, was sentenced by U.S. District Judge William Young in Boston after pleading guilty in November to seven counts of securities fraud for carrying out illicit trades that prosecutors said allowed him to earn about $1 million. Prosecutors said that from 2013 to 2014, Gadimian twice secretly traded Puma stock and options based on information he learned about positive developments regarding clinical trials involving neratinib before the company announced the news.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of PBYI earnings conference call or presentation 9-May-18 8:30pm GMT

    Q1 2018 Puma Biotechnology Inc Earnings Call

  • Here's Why Puma Biotechnology Inc. Is Sinking Today
    Motley Fool3 months ago

    Here's Why Puma Biotechnology Inc. Is Sinking Today

    The Nerlynx launch might not be progressing as well as it seems on the surface.

  • Associated Press3 months ago

    Puma Biotech: 1Q Earnings Snapshot

    The Los Angeles-based company said it had a loss of 65 cents per share. Earnings, adjusted for stock option expense, were 2 cents per share. The results surpassed Wall Street expectations. The average ...

  • Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?
    Zacks3 months ago

    Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?

    On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.

  • Puma's Shares Fall This Year Post a Solid 2017: Here's Why
    Zacks5 months ago

    Puma's Shares Fall This Year Post a Solid 2017: Here's Why

    Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.

  • Puma Biotechnology (PBYI) Up 10.2% Since Earnings Report: Can It Continue?
    Zacks5 months ago

    Puma Biotechnology (PBYI) Up 10.2% Since Earnings Report: Can It Continue?

    Puma Biotechnology (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Puma Biotechnology Inc (NASDAQ:PBYI) Is Trading At A 47% Discount
    Simply Wall St.5 months ago

    Puma Biotechnology Inc (NASDAQ:PBYI) Is Trading At A 47% Discount

    I am going to run you through how I calculated the intrinsic value of Puma Biotechnology Inc (NASDAQ:PBYI) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...

  • Does Puma Biotechnology Inc’s (NASDAQ:PBYI) -5.79% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.5 months ago

    Does Puma Biotechnology Inc’s (NASDAQ:PBYI) -5.79% Earnings Drop Reflect A Longer Term Trend?

    Examining Puma Biotechnology Inc’s (NASDAQ:PBYI) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...